Clinical research
Moderna presented more detailed data from the Phase I trial of its mRNA COVID-19 vaccine at the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today.
Takeda Pharmaceutical and Ovid Therapeutics announced on Tuesday that they have gathered positive data from their Phase II ELEKTRA study of soticlestat in children with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS).
BMS announced that the Phase III IDHENTIFY trial of Idhifa (enasidenib) plus best supportive care (BSC) compared to conventional care, did not meet the primary endpoint of overall survival in relapsed or refractory acute myeloid leukemia (r/r AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
Specifically, the trial of Spartalizumab did not meet the primary endpoint of investigator-assessed progression-free survival.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 24, 2020.
According to a report, three people briefed on the plan indicated Trump wants to give AstraZeneca and the University of Oxford’s experimental COVID-19 vaccine emergency use authorization ahead of the U.S. presidential election on November 3.
It was a relatively quiet week for clinical trial news. Here’s a look.
The trial remains on clinical hold and continues to indefinitely delay the company’s plans to seek regulatory approval for the treatment.
Following approval of its coronavirus vaccine, the first in the world, Russia plans to initiate a new study involving 40,000 people as the country looks to boost production and distribute the drug to patients in that country, as well as to patients in countries it has struck deals with.
PRESS RELEASES